Charles Theuer | President and Chief Executive Officer |
Patricia Bitar | Chief Financial Officer |
Chad Messer | Needham & Company |
Maury Raycroft | Jefferies |
Bert Hazlett | BTIG |
Nick Rubino | Stifel |
Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals First Quarter 2018 Earnings Conference Call. At this time, all callers are in a listen-only mode. After the speakers’ prepared remarks, we will conduct a question-and-answer session and instructions will be given at that time.
During today’s call, we’ll be making certain forward-looking statements, including statements regarding expected timing of clinical trials and results, regulatory activities, future expenses and cash runway, and our development plans and strategy. These statements are subject to various risks that are described in our filings made with Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2017, and subsequent quarterly reports on Form 10-Q.